https://www.selleckchem.com/pr....oducts/bgb-16673.htm
Progression occurred in 10% and 0% in the 5-10 mg and 10 mg groups 37% in the placebo group. Results with GLOBE age-specific thresholds were similar. Based on change in APRI and GLOBE score at 12 months, OCA treatment is associated with reduction in the predicted risk of liver-related complications in patients with PBC. Primary biliary cholangitis (PBC) is a chronic disease affecting the liver. People who suffer from PBC are at risk of serious long-term complications. Information from certain blood tests can be used to estimate the li
Like
Comment
Share
